The short answer
Combined hormone therapy pairs an estrogen with a progestogen to protect the uterine lining in people who still have a uterus. Products that combine both include Activella (oral estradiol + norethindrone acetate), CombiPatch (patch, estradiol + norethindrone acetate), Climara Pro (patch, estradiol + levonorgestrel), Prempro and Premphase (oral conjugated estrogens + medroxyprogesterone acetate), and Bijuva (oral estradiol + progesterone). Prefest (oral estradiol + norgestimate) is an older product with no current label listed on DailyMed as of October 2026. Duavee takes a different approach, pairing conjugated estrogens with bazedoxifene instead of a progestogen.
Each product has its own current label
As of our October 3, 2026 DailyMed check, Activella, CombiPatch, Climara Pro, and Prempro/Premphase still carry the estrogen-plus-progestin boxed warning (cardiovascular disorders, breast cancer, endometrial cancer, probable dementia). Bijuva's revised label has no boxed warning. Duavee's label carries a boxed warning for endometrial cancer, cardiovascular disorders, and probable dementia. In November 2025 the FDA asked hormone therapy manufacturers to remove some boxed-warning language, but a product's warning changes only when its own label is revised.
Common contraindications across these labels include undiagnosed abnormal genital bleeding, breast or estrogen-dependent cancer, current or past blood clots, current or past stroke or heart attack, liver disease, and pregnancy. Check the specific label.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03. Prefest (estradiol/norgestimate) had no current DailyMed label in this check.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Activella (estradiol/norethindrone acetate) tablets | 2023-11-30 | Cardiovascular disorders, probable dementia, breast cancer, endometrial cancer |
| CombiPatch (estradiol/norethindrone acetate) patch | 2024-02-21 | Cardiovascular disorders, breast cancer, endometrial cancer, probable dementia |
| Climara Pro (estradiol/levonorgestrel) patch | 2026-03-26 | Cardiovascular disorders, probable dementia, breast cancer, endometrial cancer |
| Prempro / Premphase | 2026-04-28 | Cardiovascular disorders, breast cancer, endometrial cancer, probable dementia |
| Bijuva (estradiol/progesterone) capsules | 2026-09-29 | None (revised label) |
| Duavee (conjugated estrogens/bazedoxifene) | 2026-04-28 | Endometrial cancer, cardiovascular disorders, probable dementia |
Established evidence
Why a progestogen is added
Estrogen alone stimulates the uterine lining and raises the risk of endometrial hyperplasia and cancer. A progestogen, either body-identical progesterone or a synthetic progestin, counters that effect. People without a uterus generally use estrogen alone.
Established evidence
Combination products compared
| Product | Ingredients | Form | Approved uses (women with a uterus) | Boxed warning on current label |
|---|---|---|---|---|
| Activella | Estradiol + norethindrone acetate | Daily tablet | Hot flashes; vaginal atrophy; osteoporosis prevention | Yes |
| CombiPatch | Estradiol + norethindrone acetate | Twice-weekly patch | Hot flashes; vaginal atrophy; hypoestrogenism | Yes |
| Climara Pro | Estradiol + levonorgestrel | Weekly patch | Hot flashes; osteoporosis prevention | Yes |
| Prempro / Premphase | Conjugated estrogens + medroxyprogesterone acetate | Daily tablets | Hot flashes; vaginal atrophy; osteoporosis prevention | Yes |
| Bijuva | Estradiol + progesterone | Daily capsule | Hot flashes | None (revised label) |
| Duavee | Conjugated estrogens + bazedoxifene (no progestogen) | Daily tablet | Hot flashes; osteoporosis prevention | Yes |
| Prefest | Estradiol + norgestimate (pulsed regimen) | Daily tablet | Not confirmed: no current DailyMed label | Not confirmed |
Established evidence
About Prefest
Prefest combines estradiol with norgestimate, a synthetic progestin, in a pulsed regimen of estradiol alone for three days followed by estradiol plus norgestimate for three days. It does not contain progesterone and is not the same as Prometrium or micronized progesterone. We could not find a current Prefest label on DailyMed in October 2026, so it may no longer be marketed in the U.S.; a pharmacist can confirm.
Combined products vs separate estrogen and progestogen
Many people use estradiol (as a patch, gel, or pill) with separate micronized progesterone or a levonorgestrel IUD (the IUD use is off-label for this purpose). Separate products allow independent dose changes; combined products mean fewer items. Neither approach is right for everyone.
Limited human evidence
Do progestogens differ?
Observational studies, including the French E3N cohort, associated estradiol plus micronized progesterone with lower breast cancer risk over the first years of use than some synthetic progestins. These are not randomized trials, and The Menopause Society describes the evidence as limited.
Questions to ask a healthcare professional
- A combined product or separate estrogen and progestogen?
- Pill or patch for my clot and migraine history?
- Continuous or cyclic regimen?
Questions, answered
What people ask about Activella, CombiPatch, Climara Pro, Prempro, Bijuva
Is Prefest progesterone?+
No. Prefest contains estradiol and norgestimate, a synthetic progestin.
Do I need combined therapy if I had a hysterectomy?+
Usually not. People without a uterus generally use estrogen alone.
Does Kindr Health offer these products?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Activella, CombiPatch, Climara Pro, Prempro, Bijuva on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Activella prescribing information (2023) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4b0c1dd-aae9-4ca2-958c-71dbe5d0fab0
- CombiPatch prescribing information (2024) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83198ef1-11c4-11e4-9191-0800200c9a66
- Climara Pro prescribing information (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd
- Prempro / Premphase prescribing information (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd0c0836-5d23-2183-da81-9dc7f4287052
- Bijuva prescribing information (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59eadb88-c9f3-4871-b176-7ddd98faf9bc
- Duavee prescribing information (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f
- FDA initiates removal of boxed warnings from menopausal hormone therapy products (2025) — U.S. Department of Health and Human Services / FDA. www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
- FDA approves labeling changes to menopausal hormone therapy products (first six labels) (2026) — U.S. Food and Drug Administration. www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- The 2022 hormone therapy position statement of The North American Menopause Society (2022) — The Menopause Society (Menopause journal). pubmed.ncbi.nlm.nih.gov/35797481
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.